The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

When a pharmaceutical company receives FDA approval for a new therapy, it marks the culmination of years—often over a ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) Inc on Wednesday, setting a price... Mizuho Securities analyst Salim Syed maintained a Buy rating on ...